These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18185483)

  • 1. Nonbleeding complications of unfractionated and low-molecular weight heparins.
    Eikelboom J
    Clin Adv Hematol Oncol; 2007 Nov; 5(11):871-3. PubMed ID: 18185483
    [No Abstract]   [Full Text] [Related]  

  • 2. Low molecular weight heparins--a safer option than unfractionated heparin?
    McKay GA; Paterson KR
    Adverse Drug React Toxicol Rev; 2001 Dec; 20(4):256-76. PubMed ID: 11770172
    [No Abstract]   [Full Text] [Related]  

  • 3. Current challenges of anticoagulant treatment.
    Ginghină C; Giuşcă S; Serban M; Popescu BA; Jurcuţ R; Uscăţescu V
    Rom J Intern Med; 2007; 45(3):221-7. PubMed ID: 18333353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT).
    Rota E; Bazzan M; Fantino G
    Thromb Haemost; 2008 Apr; 99(4):779-81. PubMed ID: 18392338
    [No Abstract]   [Full Text] [Related]  

  • 5. Heparin induced thrombocytopenia after low molecular weight heparin treatment: a case report.
    Illuminati G; Caliò FG; Bertagni A; Forte A; Gallinaro L; Montesano G; Ciulli A
    Riv Eur Sci Med Farmacol; 1996; 18(5-6):225-8. PubMed ID: 9177626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of low-molecular-weight heparins in pregnancy--how safe are they?
    Deruelle P; Coulon C
    Curr Opin Obstet Gynecol; 2007 Dec; 19(6):573-7. PubMed ID: 18007136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allergy to heparins and anticoagulants with a similar pharmacological profile: an update.
    Jappe U
    Blood Coagul Fibrinolysis; 2006 Nov; 17(8):605-13. PubMed ID: 17102645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux.
    Harr T; Scherer K; Tsakiris DA; Bircher AJ
    Allergy; 2006 Jun; 61(6):787-8. PubMed ID: 16677252
    [No Abstract]   [Full Text] [Related]  

  • 9. [Present opinions concerning the administration of low molecular weight heparins in hemodialysis patients].
    Drozdz M; Kowalczyk-Michałek M; Kraśniak A; Sułowicz W
    Przegl Lek; 2005; 62(4):257-9. PubMed ID: 16229247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemorrhagic complications of low molecular weight heparins (LMWHs).
    Ellis MH
    Isr Med Assoc J; 2005 Dec; 7(12):822-3. PubMed ID: 16382711
    [No Abstract]   [Full Text] [Related]  

  • 11. Low-molecular-weight heparin in pregnancy.
    Kittisupamongkol W
    Am J Obstet Gynecol; 2009 Sep; 201(3):e12; author reply e12. PubMed ID: 19439265
    [No Abstract]   [Full Text] [Related]  

  • 12. The effects of heparin and low molecular weight heparins on bone.
    Rajgopal R; Bear M; Butcher MK; Shaughnessy SG
    Thromb Res; 2008; 122(3):293-8. PubMed ID: 17716711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Need for more intensive treatment of patients with acute pulmonary embolism caused by heparin-induced thrombocytopaenia Type II.
    Antonijevic NM; Milosevic R; Perunicic J; Stanojevic M; Calija B; Vasiljevic Z
    Eur Heart J; 2005 Dec; 26(24):2745-6. PubMed ID: 16230301
    [No Abstract]   [Full Text] [Related]  

  • 14. [Low molecular weight heparin, fondaparinux and melagatran: new data and clinical studies].
    Bauersachs RM
    Pharm Unserer Zeit; 2004; 33(3):206-18. PubMed ID: 15208909
    [No Abstract]   [Full Text] [Related]  

  • 15. [Low-molecular-weight heparins versus unfractionated heparin for treatment of hemodialysed patients].
    Kes P; Basić-Jukić N; Jurić I
    Lijec Vjesn; 2007; 129(8-9):305-8. PubMed ID: 18198633
    [No Abstract]   [Full Text] [Related]  

  • 16. A benchmark for platelet count monitoring with low-molecular-weight heparin: expanding implementation of National Patient Safety Goals.
    Spinler SA
    Ann Pharmacother; 2009 Sep; 43(9):1519-21. PubMed ID: 19690223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of unfractionated heparin and long-term treatment with low-molecular-weight heparin, bemiparin, on potassium levels.
    Rocha E; Gómez-Outes A; Martínez González J; Kakkar VV
    Thromb Haemost; 2005 Nov; 94(5):1109-10. PubMed ID: 16363259
    [No Abstract]   [Full Text] [Related]  

  • 18. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Commentary.
    Gómez-Outes A; Gómez de la Bárcena C; Martínez-González J
    Br J Dermatol; 2008 Apr; 158(4):869-70. PubMed ID: 18284394
    [No Abstract]   [Full Text] [Related]  

  • 19. Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital.
    Ban-Hoefen M; Francis C
    Thromb Res; 2009 Jun; 124(2):189-92. PubMed ID: 19195684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thromboembolic disease and thrombocytopenia associated with the use of low-molecular weight heparins].
    Bóveda Treviño JL; Gràcia Gozalo RM; Barrabés J; Monasterio J
    Med Clin (Barc); 1991 May; 96(18):718-9. PubMed ID: 1649359
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.